Back to today’s briefing

Story perspectives

AbbVie Invests $650M in RemeGen’s Cancer Treatment Deal

1/14/2026

40 9 Full Breakdown

Summary

Story summary

AbbVie Inc. entered a licensing agreement with RemeGen Co., Ltd. for RC148, paying $650 million upfront.
The deal could yield up to $4.95 billion in milestones and royalties.
RC148 is a bispecific antibody targeting PD-1 and VEGF, under investigation for various solid tumors.
AbbVie plans to acquire a device manufacturing plant in Tempe, Arizona, investing more than $175 million and creating about 200 jobs.

1 of 1

Story summary

AbbVie Inc. entered a licensing agreement with RemeGen Co., Ltd. for RC148, paying $650 million upfront.
The deal could yield up to $4.95 billion in milestones and royalties.
RC148 is a bispecific antibody targeting PD-1 and VEGF, under investigation for various solid tumors.
AbbVie plans to acquire a device manufacturing plant in Tempe, Arizona, investing more than $175 million and creating about 200 jobs.